Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CareDx Showcases Cellular Transplantation and Therapy Portfolio at TCT
CareDx, Inc.February 5, 2021 GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced plans to showcase the CareDx Cellular Transplant Therapies portfolio at the Transplantation and Cellular Therapy Meeting (TCT) February 8-12, 2021.
CareDx will have four abstracts presented in poster presentations. One poster will be presented in partnership with Atara Biotherapeutics on the potential use of AlloCell for standardized pharmacokinetic assessment in a clinical trial. The other posters will highlight data on AlloHeme and AlloSeq HCT for chimerism and recurrence surveil